Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Kaubisch · SciRah

Researcher profile · Semantic Scholar

A. Kaubisch

Share profile

A. Kaubisch — researcher profile on SciRah

h-index: 21
Works: 102
Citations: 3,959

Most-cited papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
A. Zhu, R. Finn, J. Edeline, S. Cattan +55 more
2018The Lancet Oncology2,089 citations
Semantic Scholar
Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.
C. Hesdorffer, Janet Ayello, M. Ward, A. Kaubisch +7 more
1998Journal of Clinical Oncology223 citations
Semantic Scholar
Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice.
Hongwei Wang, M. Venkatesh, Hao Li, R. Goetz +12 more
2011Journal of Clinical Investigation135 citations Open access
Semantic Scholar
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
M. Moehler, Jeong Heo, H. Lee, W. Tak +33 more
2019Oncoimmunology120 citations Open access
Semantic Scholar
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
T. Hobday, R. Qin, D. Reidy-Lagunes, M. Moore +7 more
2015Journal of Clinical Oncology120 citations Open access
Semantic Scholar
Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
G. Abou-Alfa, Donna Niedzwieski, J. Knox, A. Kaubisch +16 more
2016110 citations
Semantic Scholar
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.
G. Abou-Alfa, Q. Shi, J. Knox, A. Kaubisch +23 more
2019JAMA Oncology105 citations Open access
Semantic Scholar
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
J. Kortmansky, M. Shah, A. Kaubisch, Amanda R. Weyerbacher +11 more
2005Journal of Clinical Oncology104 citations
Semantic Scholar
PTEN GENE EXPRESSION AND MUTATIONS IN THE PIK3CA GENE AS PREDICTORS OF CLINICAL BENEFIT TO ANTI EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY THERAPY IN PATIENTS WITH KRAS WILD TYPE METASTATIC COLORECTAL CANCER
Arjun Sood, D. McClain, R. Maitra, A. Basu-Mallick +6 more
2012Clinical colorectal cancer101 citations Open access
Semantic Scholar
Enhanced antigen immunogenicity induced by bispecific antibodies
D. Snider, A. Kaubisch, D. Segal
1990Journal of Experimental Medicine67 citations Open access
Semantic Scholar
Who Benefits from Adjuvant Radiotherapy for Gastric Cancer?: A Meta-Analysis
N. Ohri, M. Garg, S. Aparo, A. Kaubisch +4 more
2013International Journal of Radiation Oncology, Biology, Physics57 citations Open access
Semantic Scholar
Phase II Study of Paclitaxel plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma
A. Lam, J. Sparano, V. Vinciguerra, A. Ocean +6 more
2009American Journal of Clinical Oncology44 citations Open access
Semantic Scholar
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
He-Rui Yao, M. Yan, Z. Tong, Xin-Hong Wu +29 more
2024Journal of Clinical Oncology42 citations
Semantic Scholar
Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineere monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors.
Swati Goel, R. Bauer, K. Desai, A. Bulgaru +7 more
2007Annals of Oncology30 citations Open access
Semantic Scholar
A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma
J. Knox, R. Qin, J. Strosberg, B. Tan +6 more
2015Investigational new drugs29 citations
Semantic Scholar
Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
A. Kaubisch, G. Schwartz
2000Cancer Journal28 citations
Semantic Scholar
Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation.
Maria M. Zlobinsky Rubinstein, A. Kaubisch, M. Kinkhabwala, J. Reinus +2 more
2016Journal of Gastrointestinal Oncology26 citations Open access
Semantic Scholar
Value of noncontrast CT immediately after transarterial chemoembolization of hepatocellular carcinoma with drug-eluting beads.
Y. Golowa, J. Cynamon, J. Reinus, M. Kinkhabwala +4 more
2012Journal of Vascular and Interventional Radiology25 citations
Semantic Scholar
A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study.
D. Catenacci, N. Bahary, M. Edelman, S. Nattam +14 more
201224 citations
Semantic Scholar
Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer: A Brown University Oncology Group Phase II Study
H. Safran, K. Charpentier, A. Kaubisch, Kalyan C Mantripragada +15 more
2015American Journal of Clinical Oncology21 citations
Semantic Scholar
Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).
T. Hobday, R. Qin, D. Reidy, M. Moore +7 more
2012Journal of Clinical Oncology21 citations
Semantic Scholar
Exacerbation of psoriasis following COVID‐19 vaccination in a patient previously treated with PD‐1 inhibitor
K. Mieczkowska, A. Kaubisch, B. McLellan
2021Dermatologic Therapy20 citations Open access
Semantic Scholar
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin
D. Rao, A. Mallick, Titto Augustine, C. Daroqui +14 more
2019OncoTarget16 citations Open access
Semantic Scholar
The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in An Ethnically Diverse Patient Population with Advanced Pancreatic Cancer
M. Shusterman, Erin Jou, A. Kaubisch, J. Chuy +6 more
2019Journal of Gastrointestinal Cancer15 citations
Semantic Scholar
Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer.
M. Einstein, R. Wenham, R. Morgan, M. Cristea +6 more
201215 citations
Semantic Scholar
A Phase I Trial of Oblimersen Sodium in Combination With Cisplatin and 5-Fluorouracil in Patients with Advanced Esophageal, Gastroesophageal Junction and Gastric Carcinoma
R. Raab, J. Sparano, A. Ocean, P. Christos +3 more
2010American Journal of Clinical Oncology15 citations Open access
Semantic Scholar
Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma
K. English, N. Brodin, V. Shankar, Shao-Yu Zhu +10 more
2020JAMA Network Open13 citations Open access
Semantic Scholar
Radiation Recall Dermatitis in Patients Treated with Sorafenib
K. Mehta, A. Kaubisch, Justin Tang, A. Pirlamarla +1 more
2018Case Reports in Oncological Medicine12 citations Open access
Semantic Scholar
Phase I Trial of Triapine–Cisplatin–Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers
C. Kunos, E. Chu, D. Makower, A. Kaubisch +2 more
2017Frontiers in Oncology12 citations Open access
Semantic Scholar
Targeted Therapy for Hepatocellular Carcinoma.
N. Ohri, A. Kaubisch, M. Garg, C. Guha
2016Seminars in Radiation Oncology12 citations
Semantic Scholar
Survival analysis of Hispanics in a cohort of patients with hepatocellular carcinoma
S. Aparo, S. Goel, Daniel Lin, N. Ohri +3 more
2014Cancer11 citations Open access
Semantic Scholar
Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors
A. Kaubisch, R. Kaleya, H. Haynes, A. Rozenblit +1 more
2004Cancer Chemotherapy and Pharmacology11 citations
Semantic Scholar
Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in?
J. Gans, J. Lipman, Y. Golowa, M. Kinkhabwala +1 more
2019Seminars in nuclear medicine10 citations
Semantic Scholar
Association between neutrophil–lymphocyte ratio, socioeconomic status, and ethnic minority with treatment outcome in hepatocellular carcinoma
Yifei Zhang, N. Brodin, N. Ohri, S. Thibaud +5 more
2019Hepatology International8 citations
Semantic Scholar
Centers with more therapeutic modalities are associated with improved outcomes for patients with hepatocellular carcinoma.
Julie M. Jiang, N. Ohri, Justin Tang, Renée M. Moadel +6 more
2019Journal of Gastrointestinal Oncology8 citations Open access
Semantic Scholar
Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer
S. Goel, A. Negassa, A. Khot, Dharmendra Goyal +11 more
2017Clinical colorectal cancer8 citations
Semantic Scholar
A phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in patients with advanced hepatocellular carcinoma (HCC).
Jennifer J. Knox, R. Qin, J. Strosberg, A. Kaubisch +3 more
20128 citations
Semantic Scholar
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers
S. Goel, K. Desai, S. Karri, R. Gollamudi +8 more
2007Investigational new drugs8 citations
Semantic Scholar
A Phase II Study of Bevacizumab & Temsirolimus in Advanced Extra-Pancreatic Neuroendocrine Tumors
Sonia M Abuzakhm, V. Sukrithan, B. Fruth, R. Qin +12 more
2023Endocrine-Related Cancer7 citations Open access
Semantic Scholar
Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib.
H. Safran, K. Charpentier, A. Kaubisch, G. Dubel +15 more
2010Journal of Clinical Oncology7 citations
Semantic Scholar
SURVIVAL OUTCOME AND PROGNOSTIC MODEL OF PATIENTS WITH COLORECTAL CANCER ON PHASE 1 TRIALS
A. Kam, Gopichand Pendurti, U. Shah, M. Ghalib +7 more
2018Investigational new drugs6 citations Open access
Semantic Scholar
Lenalidomide for second-line treatment of advanced hepatocellular cancer (HCC): A Brown University Oncology Group phase II study.
H. Safran, K. Charpentier, A. Kaubisch, G. Dubel +16 more
20126 citations
Semantic Scholar
Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): Results of a planned interim efficacy analysis.
T. Hobday, R. Qin, D. Reidy, M. Moore +7 more
20125 citations
Semantic Scholar
Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC).
Arjun Sood, D. McClain, R. Seetharam, M. Al-rahamneh +5 more
20105 citations
Semantic Scholar
Phase II trial of FOLFOX6, bevacizumab and cetuximab in patients with Colorectal Cancer
A. Ocean, K. O’Brien, J. Lee, N. Matthews +6 more
20075 citations
Semantic Scholar
Up‐regulation of amphotrophic retroviral receptor expression in human peripheral blood CD34+ cells
A. Kaubisch, M. Ward, Stuti Schoetz, C. Hesdorffer +1 more
1999American journal of hematology/oncology5 citations Open access
Semantic Scholar
Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
A. Acuna-Villaorduna, V. Shankar, Michael Wysota, Amanda Jirgal +7 more
2022Cancer Control: Journal of the Moffitt Cancer Cente4 citations Open access
Semantic Scholar
Arsenic trioxide (ATO) in metastatic hormone-refractory prostate cancer (HRPC): Results of phase II trial T99-0077.
R. Gallagher, A. Ferrari, A. Kaubisch, D. Makower +6 more
2004Journal of Clinical Oncology4 citations
Semantic Scholar
Arsenic trioxide (ATO) in metastatic hormone-refractory prostate cancer (HRPC): Results of phase II trial T99–0077
R. Gallagher, A. Ferrari, A. Kaubisch, D. Makower +6 more
20044 citations
Semantic Scholar
Malignant portal vein tumor thrombosis (PVTT) in patients with hepatocellular (HCC) carcinoma: Insights from a Western single-institutional cohort.
S. Vikash, F. Bteich, Julie M. Jiang, D. Kanmaniraja +4 more
2023Journal of Clinical Oncology3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Rajdev×10
Invite
L. Rajdev — researcher profile on SciRah
S. Goel×10
Invite
S. Goel — researcher profile on SciRah
S. Aparo×8
Invite
S. Aparo — researcher profile on SciRah
R. Qin×7
Invite
R. Qin — researcher profile on SciRah

×7

Invite

C. Erlichman — researcher profile on SciRah

Invite

N. Ohri — researcher profile on SciRah

M. Kinkhabwala×6

Invite

M. Kinkhabwala — researcher profile on SciRah

Invite

J. Chuy — researcher profile on SciRah

J. Strosberg×5

Invite

J. Strosberg — researcher profile on SciRah

Invite

H. Kindler — researcher profile on SciRah

Invite

M. Garg — researcher profile on SciRah

Invite

C. Guha — researcher profile on SciRah